BCDA Stock Analysis: Buy, Sell, or Hold?
BCDA - BioCardia, Inc. Common Stock
$0.93
0.05 (5.56%)
â˛
5d:
-2.18%
30d:
+6.01%
90d:
-13.19%
WAIT
LOW Confidence
Analysis Updated: Aug 13, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When BCDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BCDA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BCDA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: BCDA is currently trading at $0.93, which is considered fair relative to its 30-day fair value range of $0.81 to $0.98.
Technical Outlook: Technically, BCDA is in a strong downtrend. Immediate support is located at $0.79, while resistance sits at $0.99. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: BCDA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.50 (+1568.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCDA is in a strong downtrend. Immediate support is located at $0.79, while resistance sits at $0.99. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: BCDA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.50 (+1568.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.81 -
$0.98
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.6%)
- BULLISH: Trading 1568.6% below Wall St target ($15.50)
- WARNING: Composite score 32/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.81 -
$0.98
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.79
Resistance Level
$0.99
Current Trend
Strong Downtrend
Technical data as of
Aug 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.55
Wall Street Target
$15.50
(+1568.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 14, 2026 12:15 AM ET
Data refreshes hourly during market hours. Next update: 1:15 AM
Data refreshes hourly during market hours. Next update: 1:15 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCDA showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Peter Altman
BUY
400 shares
2026-04-21
Peter Altman
BUY
600 shares
2026-04-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$88 | 35 SELL |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 63 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 51 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 43 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$140 | 62 BUY |